el
present
recog
una
de
bacteriano
dado
el
la
importancia
que
tienen
para
la
salud
la
infeccion
producida
por
bacteriano
con
nuevo
mecanismo
de
virulencia
yo
nuevo
mecanismo
de
resistencia
lo
antimicrobiano
un
grupo
multidisciplinario
de
con
experiencia
en
enfermedad
infecciosa
una
en
la
que
se
revisaron
lo
important
en
est
campo
publicado
en
el
contenido
de
cada
uno
de
lo
seleccionado
fue
expuesto
discutido
por
uno
de
lo
miembro
del
grupo
est
revisa
alguna
de
la
enfermedad
infecciosa
bacteriana
que
suponen
hoy
en
alguno
de
lo
principal
reto
para
la
salud
e
incluy
la
infeccion
producida
por
staphylococcu
aureu
resistent
meticilina
de
comunitaria
la
producida
por
variant
de
colonia
de
aureu
la
relacionada
con
estafilococo
coagulasa
negativa
multirresistent
la
la
listeriosi
humana
la
la
to
ferina
la
infeccion
por
haemophilu
influenza
la
de
la
bacteria
productora
de
blee
la
infeccion
por
bacilo
gramnegativo
fermentador
tra
la
de
la
actual
se
discuten
comentan
diferent
relacionado
con
esto
aspecto
palabra
clave
infeccion
bacteriana
resistencia
sarm
de
comunitaria
variant
de
colonia
de
staphylococcu
aureu
resistencia
linezolid
vacuna
listeria
monocytogen
neisseria
meningitidi
haemophilu
influenza
bordetella
pertussi
escherichia
coli
klebsiella
pneumonia
productor
de
blee
pseudomona
aeruginosa
acinetobact
baumannii
import
paper
produc
field
articl
analyz
discuss
one
member
panel
paper
focu
varieti
diseas
pose
major
clinic
public
health
challeng
today
includ
infect
produc
communityacquir
methicillinresist
staphylococcu
aureu
aureu
small
coloni
variant
infect
produc
multipli
resist
coagulaseneg
staphylococci
pneumococc
infect
human
listeriosi
meningococc
diseas
haemophilu
influenza
pertussi
escherichia
coli
esblproduc
organ
infect
due
nonferment
review
state
art
paper
select
field
discuss
although
predict
centuri
indic
incid
infecti
diseas
would
diminish
result
improv
sanit
introduct
mani
vaccin
antibiot
begin
centuri
rate
infect
produc
new
pathogen
reemerg
microorgan
possess
new
virul
resist
phenotyp
increas
threaten
overal
human
health
last
year
move
preantibiot
era
antibiot
era
era
emerg
infecti
diseas
discoveri
new
infecti
diseas
steadi
increas
number
microorgan
resist
multipl
antimicrobi
agent
alter
practic
medicin
within
hospit
affect
manag
infect
ambulatori
care
set
scenario
communityacquir
methicillinresist
staphylococcu
aureu
camrsa
emerg
common
pathogen
isol
patient
skin
softtissu
infect
attend
emerg
depart
mani
unit
state
australian
citi
present
incid
increas
part
world
despit
grow
preval
mrsa
hospit
strain
uncommon
commun
mani
circumst
mrsa
escap
commun
patient
still
harbour
organ
discharg
hospit
personnel
go
work
home
strain
associ
infect
begin
commun
isol
hospitalassoci
howev
increas
number
report
mrsa
infect
commun
escap
hospit
longer
mrsa
consid
exclus
nosocomi
pathogen
molecular
evid
strain
mrsa
also
evolv
commun
well
adapt
surviv
caus
epidem
outsid
hospit
camrsa
infect
refer
mrsa
infect
patient
lack
establish
mrsa
risk
factor
without
previou
histori
mrsa
infect
colon
medic
histori
past
year
hospit
healthcarerel
admiss
nurs
home
skill
nurs
facil
hospic
dialysi
surgeri
implant
perman
indwel
cathet
medic
devic
camrsa
tend
caus
infect
occur
cluster
small
outbreak
affect
otherwis
healthi
uniqu
popul
children
young
adult
australian
aborigin
nativ
american
alaskan
nativ
prison
militari
recruit
men
sex
men
colleg
athlet
player
compet
contact
sport
recent
antimicrobi
exposur
less
like
report
risk
mrsa
infect
commun
health
care
set
infect
mild
limit
skin
soft
tissu
though
rapidli
fatal
invas
infect
necrot
fasciiti
overwhelm
pneumonia
sepsi
accompani
waterhousefriderichsen
syndrom
occur
may
serv
sentinel
first
bring
widespread
commun
problem
attent
public
health
personnel
skin
infect
caus
organ
often
necrot
center
diseas
misdiagnos
spider
bite
similar
epidemiolog
methicillinsuscept
aureu
camrsa
infect
occur
children
differ
region
unit
state
throughout
world
although
minor
skin
softtissu
infect
predomin
lifethreaten
invas
diseas
death
result
children
camrsa
caus
septic
thrombophleb
extrem
pelvic
syndrom
consist
septic
arthriti
hip
osteomyel
pelvic
bone
pelvic
abscess
septic
thrombophleb
unlik
hospit
strain
typic
resist
multipl
antimicrobi
agent
share
common
genotyp
hospit
isol
commun
acquir
strain
tend
suscept
nonbetalactam
genotyp
distinct
hospit
isol
commun
two
main
clone
usa
usa
belong
mlst
respect
describ
respons
major
infect
caus
camrsa
throughout
unit
state
contin
frequent
st
camrsa
southwest
pacif
clone
european
clone
although
europ
clone
also
describ
meca
gene
genet
determin
necessari
express
oxacillin
resist
resid
strain
genet
element
usual
sccmec
type
iv
v
differ
encod
methicillin
resist
hospitalacquir
mrsa
although
recent
year
sccmec
type
iv
frequent
found
nosocomi
mrsa
isol
mainli
europ
anoth
key
differ
almost
camrsa
isol
contain
gene
encod
pantonvalentin
leukocidin
cytotoxin
caus
leukocyt
destruct
tissu
necrosi
although
exact
role
pantonvalentin
leukocidin
seriou
infect
caus
organ
unclear
gener
marker
camrsa
hypothesi
order
explain
origin
camrsa
meca
gene
sccmec
transfer
horizont
one
previous
oxacillinsuscept
aureu
strain
occupi
tradit
commun
nich
possibl
account
distinct
phenotyp
genotyp
characterist
camrsa
rel
long
time
lag
appear
mrsa
hospit
emerg
commun
may
part
due
low
frequenc
horizont
chromosom
gene
transfer
present
knowledg
camrsa
epidemiolog
incomplet
add
challeng
control
infect
addit
nasal
colon
may
preced
camrsa
infect
sinc
nasal
carriag
prime
predictor
subsequ
infect
difficult
identifi
control
popul
risk
colon
gastrointestin
tract
household
pet
may
act
addit
reservoir
camrsa
moreov
camrsa
introduc
hospit
thu
blur
border
communityacquir
hospitalacquir
strain
therapi
infect
due
camrsa
includ
appropri
drainag
skin
softtissu
lesion
sinc
milder
infect
often
respond
local
incis
drainag
alon
clinician
know
use
drug
activ
camrsa
clindamycin
minocyclin
doxycyclin
trimethoprimsulfamethoxazol
vancomycin
although
optim
antimicrobi
agent
therapi
unknown
sever
invas
infect
therapi
vancomycin
linezolid
immedi
start
sinc
antimicrobi
agent
may
ineffect
patient
receiv
treatment
late
recognit
partial
vancomycin
resist
may
result
vancomycin
treatment
failur
seriou
mrsa
infect
portend
nearterm
loss
firstlin
drug
treatment
choic
vancomycinintermedi
aureu
visa
heterogen
visa
hvisa
becom
signific
problem
mani
part
world
visahvisa
isol
aris
fulli
vancomycinsuscept
aureu
persist
infect
fail
respond
glycopeptid
therapi
associ
signific
phenotyp
chang
resist
may
develop
differ
pathway
strain
thicken
cell
wall
reduc
peptidoglycan
crosslink
lead
cell
wall
clog
vancomycin
moreov
mark
reduct
autolyt
activ
reduc
cell
wall
turnov
found
visa
hvisa
strain
sever
studi
demonstr
number
metabol
pathway
regulatori
gene
may
contribut
resist
particular
agr
twocompon
regulatori
system
link
lowlevel
vancomycin
resist
aureu
report
suggest
agr
type
ii
strain
loss
agr
function
associ
visa
also
note
mani
report
visa
infect
involv
biomed
devic
biofilm
format
devic
could
import
initi
step
pathway
vancomycin
resist
emerg
pathogen
seen
wellknown
pathogen
newli
discov
subpopul
parent
strain
abl
produc
diseas
staphylococcu
aureu
smallcoloni
variant
scv
fall
categori
variant
subpopul
defect
electron
transport
grow
slowli
produc
coloni
size
parent
strain
grown
medium
amount
time
clinic
isol
synthes
menadion
hemin
result
block
electron
transport
level
menaquinon
cytochrom
scv
might
seem
less
virul
slow
growth
decreas
product
coagulas
alphatoxin
howev
intracellular
locat
scv
shield
host
defens
slow
growth
reduc
efficaci
cell
wallact
antibiot
decreas
membran
potenti
protect
posit
charg
antimicrobi
scv
repres
subpopul
aureu
caus
persist
recurr
infect
overal
preval
firmli
establish
problem
discov
identifi
organ
may
caus
underestim
preval
coagulaseneg
staphylococci
also
seen
emerg
pathogen
sinc
acquir
new
virul
factor
resist
new
antimicrobi
microorgan
colon
indwel
cathet
includ
central
venou
cathet
form
biofilm
result
bloodstream
infect
organ
embed
matrix
extracellular
polymer
substanc
produc
exhibit
alter
phenotyp
respect
growth
rate
gene
transcript
treatment
infect
convent
antimicrobi
agent
alon
frequent
unsuccess
due
high
toler
agent
microorgan
compris
biofilm
sever
prevent
treatment
approach
investig
catheterrel
infect
includ
recent
renew
interest
use
bacteriophag
mitig
biofilm
format
indwel
cathet
recent
anoth
caus
concern
among
coagulaseneg
staphylococci
resist
new
antimicrobi
agent
linezolid
although
resist
linezolid
infrequ
among
staphylococci
organ
abl
acquir
de
novo
resist
among
patient
long
durat
hospit
receiv
high
amount
linezolid
moreov
linezolidresist
strain
transmit
patienttopati
establish
part
skin
flora
may
precursor
linezolidresist
mrsa
streptococcu
pneumonia
caus
seriou
infect
major
sourc
morbid
mortal
among
age
group
develop
develop
world
addit
emerg
strain
highlevel
resist
penicillin
antimicrobi
agent
rais
concern
current
futur
effect
antibiot
regimen
nevetheless
evid
decreas
resist
antimicrobi
region
world
reduct
antimicrobi
use
commun
set
associ
declin
resist
pneumococci
class
antimicrobi
mainli
betalactam
howev
still
wit
relentless
increas
resist
macrolid
class
antimicrobi
fortun
control
pneumococc
diseas
vaccin
polysaccharid
vaccin
adult
demonstr
reduct
risk
bacterem
pneumococc
diseas
vaccin
well
decreas
risk
death
complic
hospit
reinforc
need
improv
complianc
exist
pneumococc
vaccin
recommend
adult
moreov
introduct
pneumococc
conjug
vaccin
prevent
invas
diseas
children
also
appear
result
declin
preval
resist
serotyp
includ
vaccin
result
overal
decreas
preval
pneumococc
resist
howev
penicillinnonsuscept
pneumococc
clone
nonvaccin
serotyp
report
caus
bacteremia
infect
clone
may
deriv
capsular
transform
vaccinerel
serotyp
recent
year
upsurg
incid
human
listeriosi
seem
occur
geograph
area
although
case
foodborn
epidemiolog
complex
prevent
diseas
must
includ
dietari
advic
avoid
highrisk
food
routin
pregnant
women
elderli
immunocompromis
patient
listeriosi
manifest
primarili
abort
septicemia
central
nervou
system
infect
high
casefat
rate
patient
group
listeria
monocytogen
third
common
caus
bacteri
mening
occur
among
immunocompromis
patient
elderli
individu
symptom
sign
patient
present
l
monocytogen
mening
differ
found
gener
popul
patient
communityacquir
bacteri
mening
albeit
longer
prodrom
phase
howev
typic
cerebrospin
fluid
find
predict
bacteri
mening
might
absent
gram
stain
low
yield
patient
age
year
old
risk
factor
l
monocytogen
mening
amoxicillinbas
empir
antimicrobi
regimen
mandatori
sinc
bacterium
resist
cephalosporin
despit
avail
decad
meningococc
vaccin
neisseria
meningitidi
remain
lead
caus
mening
sepsi
seriou
infect
industri
nation
develop
world
group
c
meningococc
conjugatevaccin
effect
unit
kingdom
declin
first
year
year
immun
infant
immun
month
age
toddler
given
singl
dose
recent
studi
find
evid
lower
immun
children
immun
infant
toddler
basi
serum
bactericid
activ
andor
passiv
protect
age
group
protect
year
immun
significantli
greater
unimmun
histor
control
studi
snape
et
al
antibodi
respons
either
reduc
dose
meningococc
c
polysaccharid
vaccin
meant
simul
exposur
n
meningitidi
meningococc
c
conjug
vaccin
healthi
unit
kingdom
prime
serogroup
c
conjug
vaccin
year
previous
add
new
data
number
day
requir
antibodi
level
increas
boost
either
vaccin
addit
suscept
associ
flaw
complement
pathway
function
sever
pathway
also
convincingli
link
alter
host
suscept
meningococc
diseas
articl
jack
et
al
break
new
ground
increas
understand
human
genet
basi
host
defenc
failur
meningococc
diseas
surfact
protein
sp
spd
patternrecognit
molecul
respiratori
tract
activ
inflammatori
phagocyt
defenc
bind
microbi
sugar
variat
gene
surfact
protein
affect
express
function
molecul
routin
use
haemophilu
influenza
type
b
hib
conjug
vaccin
dramat
decreas
incid
invas
hib
diseas
western
world
despit
effect
vaccin
increas
incid
hib
diseas
recent
observ
european
countri
care
analysi
circul
hib
strain
essenti
prompt
detect
chang
properti
bacteria
enabl
particular
clone
overcom
host
immun
respons
recent
italian
studi
contrari
previou
report
neither
increas
genet
divers
hib
strain
isol
children
disappear
individu
clone
observ
rountin
immun
infant
hib
establish
howev
upward
tempor
trend
proport
strain
possess
multipl
copi
capsul
b
locu
detect
result
studi
suggest
vaccin
pressur
may
posit
select
strain
harbour
amplifi
cap
b
sequenc
interact
nontyp
haemophilu
influenza
nthi
human
alveolar
macrophag
implic
persist
nthi
chronic
obstruct
pulmonari
diseas
copd
recent
studi
sethi
group
confirm
hypothesi
immunolog
respons
alveolar
macrophag
nthi
impair
copd
group
describ
phenotyp
variant
nthi
haemophilu
haemolyticu
frequent
colon
airway
copd
patient
found
normal
steril
site
find
substanti
strengthen
associ
true
h
influenza
clinic
infect
exacerb
chronic
bronchiti
control
pertussi
infect
optim
neither
vaccin
natur
infect
induc
longliv
immun
increas
proport
report
pertussi
case
involv
adolesc
adult
aim
recent
us
studi
defin
among
unimmun
control
subject
yearli
infect
rate
character
proport
infect
includ
prolong
cough
similar
analysi
attempt
acellular
pertussi
ap
vaccin
subject
pertussi
infect
older
person
found
larg
asymptomat
ap
booster
confer
protect
adolesc
adult
symptomat
pertussisth
diagnosi
pertussi
older
individu
problemat
lack
specif
clinic
criteria
insensit
cultur
pcr
limit
avail
standard
serolog
test
criteria
diagnosi
spanish
studi
suggest
real
timepcr
sensit
specif
test
avail
diagnosi
pertussi
direct
fluoresc
assay
abandon
three
recent
studi
escherichia
coli
infect
deserv
comment
first
two
deal
fluoroquinolon
resist
speci
first
show
increas
preval
strain
reduc
sensit
quinolon
gut
hospit
patient
second
analys
differ
similar
fluoroquinoloneresist
e
coli
human
chicken
similar
among
strain
studi
strengthen
hypothesi
anim
origin
human
strain
fluoroquinoloneresist
e
coli
third
studi
address
progress
import
infect
caus
esblproduc
e
coli
bacteremia
caus
organ
increas
given
difficulti
encount
treatment
frequent
multiresist
tradit
use
agent
reapprais
current
empir
regimen
order
good
exampl
difficulti
found
treat
esblproduc
organ
case
report
israel
patient
esblproduc
klebsiella
pneumonia
endocard
develop
resist
ciprofloxacin
piperacillintazobactam
therapi
presenc
esblproduc
enterobacteriacea
stool
human
sewag
anim
found
high
area
studi
done
farm
anim
examin
recent
spanish
studi
harbour
esblproduc
enter
bacteria
potenti
dissemin
multiresist
isol
illustr
two
recent
report
emerg
proteu
mirabili
carri
bla
metallobetalactamas
gene
first
instanc
speci
bla
bla
carbapenemaseproduc
pseudomona
aeruginosa
among
latter
emerg
resist
carbapenem
rapid
associ
resist
polimixin
problem
clinic
level
becom
insolubl
acinetobact
baumannii
recent
emerg
major
caus
hospitalacquir
infect
propens
accumul
mechan
antimicrobi
resist
lead
pandrug
resist
caus
larg
nosocomi
outbreak
often
involv
multipl
facil
problem
particularli
seriou
intens
care
set
excel
review
publish
recent
epidemiolog
control
baumannii
infect
health
care
facil
final
although
rare
communityacquir
pneumonia
due
baumannii
known
occur
retrospect
casecontrol
studi
case
communityacquir
pneumonia
control
hospit
acquir
pneumonia
hongkong
publish
group
spanish
physician
microbiologist
interest
field
bacteri
pathogen
expand
remark
paper
publish
area
follow
public
select
discuss
studi
exampl
camrsa
epidem
unit
state
present
time
popul
studi
conduct
three
unit
state
commun
establish
annual
incid
camrsa
per
isol
associ
clinic
relev
infect
current
relev
mrsa
caus
skin
softtissu
infect
demonstr
prospect
preval
studi
involv
patient
present
emerg
depart
us
citi
moran
gj
et
accord
observ
distinct
healthcar
communityassoci
mrsa
rapidli
blur
studi
demonstr
increas
incid
skin
softtissu
infect
well
incid
invas
infect
due
camrsa
current
predomin
genotyp
usa
migrat
camrsa
strain
healthcar
set
stapylococcu
aureu
infrequ
caus
communityacquir
pneumonia
cap
recogn
caus
influenzaassoci
cap
mrsa
commonli
caus
nosocomi
pneumonia
rel
case
mrsa
cap
report
influenza
season
case
cap
due
aureu
report
cdc
state
caus
mrsa
isol
avail
microbiolog
studi
present
gene
pantonvalentin
leukocidin
thirteen
admit
icu
death
occur
patient
author
suggest
empir
therapi
sever
cap
period
high
influenza
activ
includ
coverag
mrsa
countri
high
incid
camrsa
unit
state
empir
therapi
sever
cap
period
high
influenza
activ
includ
coverag
mrsa
even
patient
without
recogn
risk
factor
mrsa
sinc
infect
camrsa
strain
pyomios
acut
bacteri
infect
skelet
muscl
local
abscess
format
caus
case
aureu
acut
bacteri
myositi
less
common
muscl
infect
inflamm
extend
one
muscl
group
without
distinct
abscess
although
commonli
caus
streptococcu
pyogen
myositi
caus
aureu
describ
case
pyomios
myositi
increas
pediatr
patient
sinc
texa
hospit
increas
appear
correl
emerg
camrsa
studi
review
medic
record
patient
admit
hospit
infect
pyomyos
myositi
fortyf
case
analyz
forti
percent
neg
cultur
caus
aureu
number
case
increas
result
increas
preval
camrsa
thigh
pelvi
commonli
affect
site
fifteen
avail
aureu
isol
camrsa
communityacquir
methicillinsuscept
aureu
camssa
pfge
isol
found
carri
pantonvalentin
leukocidin
pvl
gene
patient
camrsa
andor
pvlposit
strain
requir
drainag
procedur
camssa
andor
pvlneg
strain
vs
vs
vs
respect
author
strongli
consid
coverag
mrsa
empir
treatment
regimen
vancomycin
clindamycin
infect
children
camrsa
increas
caus
pyomyos
myositi
children
although
studi
infect
caus
camrsa
pvlposit
isol
sever
caus
camssa
pvlneg
strain
addit
studi
need
find
virul
factor
associ
muscl
infect
caus
camrsa
epidemiolog
camrsa
among
healthi
children
recent
describ
howev
littl
known
camrsa
children
underli
medic
condit
author
compar
studi
clinic
molecular
epidemiolog
camrsa
children
without
risk
factor
health
careassoci
infect
rfhai
retrospect
cohort
studi
children
camrsa
infect
conduct
rfhai
includ
hospit
within
past
year
indwel
medic
devic
chronic
medic
condit
identifi
chart
review
author
identifi
episod
communityacquir
aureu
infect
caus
mrsa
studi
period
proport
aureu
infect
caus
mrsa
rose
p
increas
note
predomin
children
skin
soft
tissu
infect
rfhai
identifi
patient
camrsa
among
subject
camrsa
children
rfhai
like
invas
infect
healthi
children
versu
p
camrsa
isol
children
rfhai
similar
without
rfhai
laboratoryretain
camrsa
isol
harbor
sccmec
type
iv
cassett
almost
isol
suscept
cotrimoxazol
clindamycin
pfge
reveal
greater
molecular
divers
among
camrsa
isol
recov
children
rfhai
compar
otherwis
healthi
children
p
addit
camrsa
isol
children
rfhai
less
like
pvlposit
p
like
resist
class
antibiot
p
studi
demonstr
border
communityacquir
hospitalacquir
mrsa
strain
blur
suggest
camrsa
strain
might
becom
endem
adult
health
care
facil
also
within
paediatr
facil
camrsa
first
report
western
australia
wa
earli
indigen
peopl
live
remot
area
statewid
polici
screen
hospit
patient
staff
live
outsid
state
mrsa
prevent
establish
multidrugresist
epidem
mrsa
memrsa
howev
studi
demonstr
polici
prevent
sccmec
type
iv
type
v
mrsa
clone
commun
clone
becom
establish
wa
mrsa
isol
wa
juli
decemb
includ
studi
isol
recov
clinic
infect
control
screen
mrsa
isol
analys
sent
refer
center
camrsa
use
differ
molecular
method
total
differ
camrsa
clone
character
isol
resist
nonbetalactam
antimicrobi
drug
five
pvlposit
camrsa
clone
identifi
australian
polici
prevent
establish
memrsa
prevent
sccmec
type
iv
v
mrsa
clone
includ
nonmemrsa
camrsa
becom
establish
wa
emerg
multidrugresist
camrsa
clone
detect
pvl
toxin
gene
clone
previous
report
pvlneg
major
public
health
concern
molecular
type
import
trace
origin
isol
design
antimicrobi
drug
prescrib
polici
control
particularli
commun
studi
indic
camrsa
strain
gener
virul
hospitalacquir
mrsa
find
consist
abil
camrsa
caus
diseas
individu
without
predispos
risk
factor
although
molecular
basi
enhanc
virul
known
strong
associ
camrsa
infect
presenc
pvl
howev
role
pvl
play
pathogenesi
camrsa
test
directli
studi
author
evalu
mous
infect
model
role
pvl
virul
camrsa
well
lytic
activ
intracellular
surviv
human
polymorphonuclear
leukocyt
pmn
isogen
strain
camrsa
express
pvl
compar
virul
pvlposit
pvlneg
camrsa
repres
lead
diseasecaus
strain
unexpectedli
strain
lack
pvl
virul
mous
sepsi
abscess
model
contain
leukotoxin
isogen
pvlneg
luksfpv
knockout
strain
lethal
wildtyp
strain
sepsi
model
caus
compar
skin
diseas
moreov
lysi
pmn
pathogen
surviv
phagocytosi
similar
wildtyp
mutant
strain
although
toxin
may
highli
link
epidemiolog
marker
camrsa
strain
author
conclud
pvl
major
virul
determin
camrsa
may
pvl
contribut
specif
patholog
condit
necrot
pneumonia
diseas
test
studi
probabl
futur
studi
use
differ
anim
model
help
understand
pathogenesi
camrsa
identifi
factor
respons
type
sever
diseas
caus
emerg
pathogen
main
limit
studi
retrospect
natur
exclud
bia
unrecogn
common
factor
lead
fluoroquinolon
therapi
mrsa
acquisit
rule
addit
advers
event
associ
increas
use
antimicrobi
substitut
fluoroquinolon
need
consid
author
investig
associ
use
fluoroquinolon
recoveri
mrsa
hospit
patient
four
hospit
locat
region
franc
similar
prestudi
incid
mrsa
select
studi
manoeuvr
consist
discontinu
use
fluoroquinolon
one
hospit
studi
period
three
other
serv
control
without
chang
antibiot
polici
consequ
studi
hospit
reduc
use
fluoroquinolon
ddd
per
bedday
increas
consumpt
amoxicillinclavulan
ceftriaxon
gentamicin
amikacin
erythromycin
cotrimoxazol
intervent
period
incid
mrsa
tend
lower
studi
hospit
odd
ratio
ci
reduct
rate
fluoroquinolon
resist
occur
gramneg
bacilli
studi
centr
suffer
nosocomi
esblproduc
klebsiella
pneumonia
outbreak
intervent
period
observ
reduct
mrsa
rate
signific
although
small
interestingli
design
studi
unfortun
spontan
decreas
incid
mrsa
rather
due
absenc
use
fluoroquinolon
may
respons
observ
reduct
addit
potenti
causal
relat
chang
antibiot
polici
occurr
esblproduc
k
pneumonia
outbreak
matter
concern
howden
bp
johnson
pd
ward
pb
stinear
tp
davi
jk
isol
lowlevel
vancomycin
resist
associ
persist
methicillinresist
staphylococcu
aureu
bacteremia
antimicrob
agent
chemoth
lowlevel
vancomycinresist
staphylococcu
aureu
vancomycinintermedi
aureu
visaand
heterogen
visa
hvisa
lead
glycopeptid
treatment
failur
genet
chang
lead
hvisa
visa
clearli
determin
studi
character
five
clinic
pair
fulli
vancomycinsuscept
aureu
vssa
hvisavisa
vancomycin
mic
mgl
isol
obtain
fail
vancomycin
therapi
patient
bacteremia
due
mrsa
order
better
understand
chang
associ
type
resist
hvisavisa
phenotyp
associ
increas
cell
wall
thick
reduc
autolyt
activ
four
five
hvisavisa
strain
strike
reduct
biofilm
format
compar
parent
strain
pair
five
pair
isogen
genom
dna
microarray
comparison
suggest
major
genet
chang
requir
develop
resist
phenotyp
strain
mark
reduct
rnaiii
express
agr
gene
found
four
pair
studi
perform
detail
analysi
differ
mechan
could
explain
convers
vssa
visa
strain
mani
phenotyp
chang
consist
previou
report
howev
reduc
autolyt
activ
essenti
express
lowlevel
vancomycin
resist
aureu
use
pair
clinic
deriv
isogen
strain
vssa
hvisavisa
valuabl
resourc
elucid
genet
mechan
low
level
glycopeptid
resist
latter
staphylococcu
aureu
smallcoloni
variant
scv
abl
persist
insid
host
cell
resist
antibiot
characterist
especi
import
involv
implantassoci
infect
author
analyz
case
hipprosthesisassoci
infect
due
scv
includ
cours
prior
identif
pathogen
patient
mean
age
year
patient
experienc
treatment
failur
prior
isol
scv
despit
mani
surgic
revis
month
antibiot
transmiss
electron
microscopi
perform
biopsi
specimen
periprosthet
tissu
reveal
intracellular
cocci
fibroblast
prosthes
remov
without
implant
spacer
antimicrobi
agent
administ
week
reimplant
prosthes
perform
patient
exchang
associ
success
outcom
mean
followup
month
slow
growth
atyp
coloni
morpholog
unusu
biochem
profil
make
clinic
laboratori
personnel
like
miss
misidentifi
scv
case
poor
respons
adequ
antimicrobi
surgic
treatment
implantassoci
staphylococc
infect
clinician
clinic
laboratori
consid
special
effort
search
scv
studi
investig
unusu
high
incid
linezolid
resist
coagulaseneg
staphylococci
lrcn
centr
usa
perform
analysi
linezolid
use
retrospect
casecontrol
studi
identifi
risk
factor
epidemiolog
profil
patient
lrcn
identifi
case
patient
first
match
randomli
select
concomit
patient
hospit
ward
second
analysi
case
patient
match
patient
linezolidsuscept
cn
isol
clinic
sampl
author
report
use
linezolid
increas
ddd
per
bedday
patient
lrcn
detect
prior
use
linezolid
lrcn
identifi
blood
cultur
patient
time
consid
contamin
patient
identifi
blood
sampl
except
one
isol
staphylococcu
lugdunensi
identifi
staphylococcu
epidermidi
mic
higher
mgl
genotyp
reveal
related
strain
patient
admit
icu
compar
random
control
prior
treatment
linezolid
significantli
associ
acquisit
lrcn
odd
ratio
admiss
ward
c
odd
ratio
patient
linezolidsuscept
cn
given
linezolid
odd
ratio
paper
describ
clonal
outbreak
due
lrcn
associ
extens
use
linezolid
although
inform
provid
interest
base
experi
one
centr
short
seri
strain
clinic
infect
vitro
studi
investig
effect
bacteriophag
biofilm
format
staphylococcu
epidermidi
hydrogelco
foley
cathet
demonstr
pretreat
cathet
lytic
epidermidi
bacteriophag
prevent
format
biofilm
new
technolog
us
pretreat
cathet
surfac
antisept
antibiot
agent
show
promis
prophylaxistreat
catheterrel
infect
result
studi
highlight
potenti
phage
reduct
biofilm
develop
biomed
implant
surfac
suggest
futur
develop
catheterassoci
infect
prevent
spite
antibiot
treatment
intens
care
mortal
communityacquir
pneumonia
cap
remain
high
hand
pneumococc
vaccin
reduc
incid
pneumococc
bacteremia
high
fatal
rate
object
studi
evalu
impact
prior
pneumococc
vaccin
earli
mortal
complic
hospit
adult
cap
studi
carri
us
teach
commun
hospit
share
common
databas
total
individu
cap
identifi
incd
rev
code
enter
studi
fiveyear
period
data
obtain
systemat
use
standard
definit
train
nurs
concurr
patient
care
valid
monthli
variabl
includ
necessari
calcul
fine
score
vaccin
statu
ye
unknown
comorbid
data
microbi
etiolog
record
statist
analysi
done
multivari
logist
regress
model
vaccin
recipi
less
like
die
hospit
unvaccin
patient
adjust
ci
trend
remain
vari
assumpt
miss
vaccin
data
vaccin
also
posit
effect
risk
respiratori
failur
ci
length
stay
also
reduc
vaccin
patient
p
conclus
prior
vaccin
associ
mortal
reduct
lower
risk
complic
reinforc
effort
toward
improv
vaccin
coverag
adult
absenc
microbiolog
data
high
proport
individu
unknown
vaccin
statu
main
weak
observ
studi
casecontrol
studi
effect
pneumococc
conjug
vaccin
prevent
invas
pneumococc
diseas
children
month
old
includ
vaccin
incomplet
schedul
studi
carri
sever
urban
area
two
entir
state
usa
case
identifi
activ
surveil
program
oper
cdc
total
case
includ
control
per
case
match
age
zip
code
select
total
case
exclud
mostli
isol
avail
serotyp
whose
parent
refus
particip
serotyp
danish
scheme
suscept
test
done
cdc
state
laboratori
match
odd
ratio
calcul
use
condit
regress
model
control
underli
disord
race
sex
access
schedul
vaccin
among
variabl
effect
defin
one
minu
adjust
match
total
case
caus
serotyp
includ
vt
mostli
children
receiv
al
least
one
dose
vaccin
fulli
vaccin
effect
healthi
children
vt
strain
vaccinerel
serotyp
serogroup
differ
type
vrt
lower
effect
observ
children
underli
diseas
vt
vrt
respect
level
protect
also
lower
strain
decreas
suscept
penicillin
prevent
serotyp
infect
sever
schedul
protect
vaccin
dose
plu
booster
protect
dose
alon
summari
prevent
invas
diseas
healthi
chronic
ill
children
even
variou
standard
schedul
studi
open
new
door
prospect
studi
investig
simpler
vaccin
schedul
vaccin
fail
serotyp
less
effici
penicillin
nonsuscept
strain
observ
studi
children
hospit
philadelphia
author
aim
evalu
effect
vaccin
pneumococc
bacteremia
pnb
caus
vrt
pneumococci
non
suscept
penicillin
pnsp
postlicensur
period
vaccin
januari
may
episod
pnb
attend
pediatr
emerg
unit
revis
retrospect
well
bacteremia
caus
respiratori
bacteri
pathogen
orbp
haemophilu
influenza
neisseria
meningitidi
moraxella
catarrhali
use
nonequival
depend
variabl
purpos
statist
analysi
blood
cultur
done
accord
physician
indic
serotyp
perform
staten
seruminstitut
antisera
collect
mic
penicillin
use
etest
strip
ab
biodisk
vaccin
statu
record
among
variabl
enter
studi
overal
decreas
per
year
incid
pnb
observ
mainli
due
reduct
case
caus
vaccin
type
strain
although
shift
trend
note
incid
pnb
caus
nonvaccin
type
orbp
remain
stabl
vrt
increas
along
studi
period
serotyp
respons
case
percentag
pnsp
strain
also
increas
p
studi
call
attent
possibl
serotyp
replac
vaccin
emerg
pnb
caus
pnsp
strain
possibl
relat
select
serotyp
poor
immugen
addit
retrospect
natur
studi
limit
absenc
record
previou
vaccin
studi
popul
use
nonequival
depend
variabl
control
bias
chang
criteria
perform
blood
cultur
along
studi
period
confound
indic
main
weak
studi
although
author
believ
variabl
would
control
certain
extent
therefor
prospect
multicent
studi
subject
would
welcom
largescal
introduct
vaccin
two
effect
becom
appar
first
increas
pharyng
colon
serotyp
cover
serotyp
replac
second
acquisit
new
nonvaccin
capsul
recombin
natur
transform
clone
serotyp
swich
author
taiwan
investig
vitro
capac
clinic
strain
pneumonia
isol
area
low
coverag
becom
transform
compet
vitro
total
strain
belong
serotyp
prospect
collect
taiwanes
hospit
except
serotyp
strain
includ
compet
studi
done
use
two
variant
competencestimul
peptid
csp
plasmid
vector
genet
divers
also
studi
puls
field
gel
electrophoresi
pfge
serotyp
greatest
compet
follow
type
serotyp
also
show
highest
genet
divers
higher
proport
penicillin
nonsuscept
rate
convers
strain
belong
type
show
highest
cluster
mostli
incompet
transform
suscept
penicillin
spite
qualit
associ
serotyp
compet
resist
correl
observ
level
compet
degre
resist
penicillin
ci
way
serotyp
rel
incompet
clear
trend
higher
proport
resist
strain
higher
penicillin
mic
studi
show
certain
serotyp
lower
capac
transform
genet
stabl
resist
penicillin
rare
strain
belong
incompet
serotyp
world
compet
would
necessari
condit
suffici
explain
genet
divers
secondarili
acquisit
penicillin
resist
determin
pneumonia
streptococcu
pneumonia
lead
caus
cap
adult
bacterem
pneumococc
pneumonia
bpp
among
seriou
form
pneumococc
diseas
populationbas
casecontrol
studi
identifi
clinic
demograph
factor
associ
macrolideresist
bpp
adult
acutecar
hospit
pennsylvania
region
decemb
april
patient
includ
studi
individu
year
least
one
blood
cultur
grew
pneumonia
drawn
within
hour
hospit
admiss
resid
one
five
counti
surround
pennsylvania
bacteri
isol
confirm
laboratori
pneumonia
seventysix
patient
erythromycinresist
infect
select
casepati
studi
author
found
exposur
macrolid
six
month
preced
infect
histori
influenza
vaccin
previou
year
hispan
ethnic
independ
associ
increas
probabl
erythromycin
resist
pneumonia
infect
among
patient
report
take
antimicrobi
agent
month
preced
infect
failur
complet
cours
prescrib
drug
associ
increas
probabl
macrolid
resist
ci
howev
patient
macrolideresist
infect
report
prior
antimicrobi
drug
exposur
author
assum
discuss
potenti
bias
may
affect
assess
differ
risk
factor
futur
studi
correl
durat
therapi
risk
colon
macrolideresist
pneumococci
would
use
explor
phenomenon
incid
invas
pneumococc
diseas
ipd
children
adult
increas
winter
howev
possibl
underli
caus
care
studi
ecolog
studi
correl
populationbas
data
ipd
respiratori
viru
activ
year
metropolitan
new
south
wale
australia
climat
paramet
seven
hospit
particip
studi
may
octob
year
good
separ
respiratori
syncyti
viru
rsv
influenza
viru
activ
demonstr
children
signific
correl
rsv
activ
ipd
activ
signific
correl
influenza
viru
activ
ipd
adult
epidem
curv
rsv
influenza
viru
activ
correspond
peak
ipd
possibl
demonstr
statist
signific
correl
activ
virus
combin
climat
paramet
clear
invers
relationship
weekli
mean
minimum
maximum
temperatur
ipd
activ
adult
children
data
temperatur
geograph
area
data
obtain
introduct
vaccin
requir
confirm
find
probabl
casecontrol
studi
compar
isol
respiratori
virus
patient
ipd
match
age
sex
locat
time
control
subject
without
ipd
would
requir
specif
examin
role
respiratori
virus
play
predispos
ipd
effect
fall
temperatur
pathogen
penumonia
extens
studi
warrant
investig
human
metapneumoviru
hmpv
found
associ
lower
respiratori
tract
infect
although
pathogenesi
remain
elucid
report
respiratori
tract
infect
due
bacteri
coinfect
hmpv
hypothesisgener
studi
perform
march
octob
involv
cohort
children
south
africa
random
receiv
pneumococc
polysaccharideprotein
conjug
vaccin
placebo
hospitalis
lower
respiratori
tract
infect
lrti
test
hmpv
infect
use
nest
reversetranscript
pcr
assay
target
amplifi
fragment
hmpv
fusion
protein
gene
infect
identifi
among
episod
lrti
children
fulli
vaccin
children
incid
hospit
least
one
episod
hmpvassoci
lrti
reduc
p
overal
p
human
immunodefici
viru
hiv
uninfect
children
p
hivinfect
children
signific
reduct
incid
clinic
pneumonia
among
vaccin
recipi
overal
p
hivuninfect
children
p
hivinfect
children
p
signific
reduct
incid
hospit
hmpvassoci
bronchiol
among
vaccin
recipi
entir
studi
popul
absenc
sensit
tool
diagnos
bacteri
pneumonia
major
obstacl
order
defin
role
bacterialviru
coinfect
human
document
approxim
onethird
children
respiratori
syncyti
viru
associ
pneumonia
may
pneumococc
coinfect
result
present
studi
suggest
bacteri
coinfect
particularli
pneumococc
infect
essenti
part
pathogenesi
sever
hmpv
infect
progress
pneumonia
implic
observ
children
hospit
diagnosi
hmpvassoci
pneumonia
treat
antibiot
signific
proport
hospitalis
may
prevent
vaccin
pneumococc
vaccin
nevertheless
inform
need
order
clarifi
pathogen
mechan
mix
infect
studi
author
describ
clinic
featur
complic
treatment
outcom
episod
communityacquir
listeria
monocytogen
mening
adult
case
includ
prospect
nationwid
observ
cohort
studi
bacteri
mening
posit
lcr
cultur
perform
netherland
octob
april
period
studi
case
bacteri
mening
diagnos
caus
l
monocytogen
repres
annual
incid
l
monocytogen
mening
case
per
adult
patient
immunocompromis
year
old
patient
symptom
present
h
clinic
present
subacut
patient
symptom
day
classic
triad
stiff
neck
fever
alter
mental
statu
present
case
gram
stain
cerebrospin
fluid
csf
sampl
reveal
caus
organ
case
biochem
csf
indic
bacteri
mening
present
initi
antimicrobi
therapi
amoxicillin
base
patient
coverag
initi
antimicrobi
therapi
microbiolog
inadequ
patient
mortal
rate
patient
experienc
unfavour
outcom
inadequ
initi
antimicrobi
therapi
relat
outcom
studi
limit
due
select
patient
posit
l
monocytogen
csf
cultur
sever
patient
antimicrobi
treatment
start
csf
obtain
import
neurolog
alter
might
exclud
nevertheless
prospect
studi
confirm
typic
csf
find
predict
bacteri
mening
might
absent
biochemistri
gram
stain
contrast
previou
report
patient
mening
due
l
monocytogen
present
atyp
clinic
featur
interest
note
high
rate
patient
hyponatremia
develop
subarachnoid
hemorrhag
one
patient
complic
frequent
relat
tubercul
mening
author
review
microbiolog
epidemiolog
data
case
human
listeriosi
report
england
wale
ten
commonsourc
outbreak
affect
patient
exclud
studi
signific
increas
observ
period
compar
major
case
sporad
pregnancyrel
death
frequent
group
nonpregnancyrel
case
vs
major
sporad
case
diagnos
occur
patient
year
age
bacteriemia
without
cn
affect
without
relat
sex
race
season
year
socioeconom
differ
underli
condit
serotyp
frequent
throughout
entir
studi
increas
case
listeriosi
shown
second
period
analys
studi
could
due
increas
interest
report
ill
nonetheless
chang
pathogen
l
monocytogen
could
also
explain
result
advic
avoid
highrisk
food
peopl
advanc
age
immunocompromis
pregnant
women
plausibl
messag
studi
immun
toddler
higher
meningococc
antibodi
serum
sampl
immun
infant
author
determin
meningococc
antibodi
serum
sampl
obtain
children
immun
group
c
meningococc
vaccin
year
earlier
infant
toddlersth
geometr
mean
serum
antibodi
concentr
higher
immun
infant
immun
toddler
unimmun
histor
control
mcgml
vs
mcgml
respect
p
proport
immun
infant
bactericid
titer
consid
protect
measur
human
complement
higher
immun
toddler
vs
p
even
threshold
protect
consid
serum
bactericid
titer
respect
percentag
serum
sampl
protect
titer
immun
infant
compar
immun
toddler
p
passiv
protect
test
serum
sampl
immun
infant
serum
sampl
immun
toddler
confer
protect
group
c
bacteremia
compar
serum
sampl
unimmun
histor
control
p
evid
lower
immun
children
immun
infant
toddler
basi
serum
bactericid
activ
andor
passiv
protect
age
group
protect
year
immun
significantli
greater
unimmunis
histor
control
aim
studi
determin
hsba
human
serum
bactericid
assay
gmt
geometr
mean
titer
percentag
particip
hsba
titer
day
vaccin
menp
secondari
endpoit
determin
hsba
gmt
geometr
mean
antibodi
concentr
measur
elisa
follow
popul
vaccin
recipi
day
recipi
menp
mencv
analyz
separ
valu
day
day
vaccin
group
analyz
separ
day
blood
sampl
obtain
phase
iv
openlabel
random
compar
trail
healthi
year
old
vaccin
singl
dose
menjug
chiron
vaccin
meningococc
serogroup
ccrm
glycoconjug
vaccin
mencv
previou
immun
statu
determin
refer
central
immun
record
relev
child
health
comput
depart
subject
number
prospect
random
block
accord
computergener
block
random
scheme
alloc
equal
number
subject
group
particip
random
group
receiv
plain
polysaccharid
serogroup
c
meningococc
vaccin
menp
person
random
group
receiv
mencv
onefifth
dose
menp
use
blood
sampl
ml
obtain
prior
vaccin
twice
week
vaccin
day
vaccin
serum
sampl
analyz
menc
sba
titer
use
hsba
hsba
titer
use
indic
conserv
measur
protect
total
particip
random
group
one
hundr
seventyon
random
group
receiv
menp
random
group
ot
receiv
mencv
hsba
titer
measur
serum
sampl
particip
increas
hsba
gmt
detect
day
administr
menp
mencv
particip
demonstr
hsba
titer
day
vaccin
hsba
gmt
observ
day
follow
vaccin
mencv
higher
observ
follow
vaccin
menp
elisa
gmc
similarli
higher
day
vaccin
men
c
menp
vs
respect
studi
show
persist
sustain
level
bactericid
antibodi
least
year
vaccin
adolesc
mencv
challeng
immun
adolesc
menp
increas
sba
observ
day
vaccin
indic
immunolog
memori
may
slow
gener
protect
potenti
rapidli
invas
organ
distribut
polymorph
three
gene
spd
cohort
patient
microbiolog
proven
meningococc
diseas
studi
studi
realiz
cohort
patient
proven
meningococc
diseas
juli
novemb
wholeblood
sampl
obtain
patient
store
serogroup
infect
organ
diseas
outcom
age
patient
record
control
group
compris
healthi
volunt
sampl
chosen
random
cohort
spaspd
genotyp
total
patient
genotyp
polymorph
loci
data
spd
polymorph
avail
patient
control
group
individu
type
success
respect
type
spd
two
allel
signific
associ
suscept
meningococc
diseas
homozygos
associ
increas
risk
meningococc
diseas
ci
patient
popul
homocyg
compar
control
popul
homozygos
rare
snp
codon
associ
increas
risk
meningococc
diseas
ci
increas
risk
death
correct
age
ci
haplotyp
higher
patient
control
subject
ci
gene
polymorph
bind
domain
surfact
protein
codon
increas
suscept
meningococc
diseas
well
risk
death
era
univers
vaccin
children
h
influenza
conjug
vaccin
critic
character
current
circul
strain
detect
genet
chang
could
render
current
vaccin
longer
protect
itali
vaccin
includ
vaccin
calendar
sinc
ant
uptak
popul
expos
sinc
aim
studi
evalu
genet
capsular
structur
avail
strain
patient
invas
diseas
assess
influenc
vaccin
chang
observ
structur
genet
divers
strain
analys
pfge
capsular
chang
southern
blot
strain
isol
pre
licensur
compar
strain
isol
post
licensur
strain
pfge
total
restrict
pattern
clear
predominant
stress
almost
half
strain
restrict
pattern
indistinguish
domin
endem
clone
itali
sinc
four
strain
fromchildren
receiv
least
one
dose
vaccin
high
genet
homolog
detect
isol
amplif
locu
capsul
b
show
signific
differ
two
analys
period
thu
strain
vaccin
period
includ
children
previous
vaccin
number
copi
higher
case
compar
prevaccin
period
p
result
studi
indic
import
monitor
invas
strain
use
molecular
genet
appli
end
shown
vaccin
condit
occurr
genet
chang
disappear
domin
clone
follow
howev
relev
chang
express
capsul
gene
could
explain
least
part
lack
immun
respons
vaccin
children
nontyp
haemophilu
influenza
nthi
frequent
pathogen
patient
copd
acut
exacerb
due
bacteri
infect
nthi
frequent
isol
organ
report
nthi
isol
varieti
respiratori
sourc
studi
also
microbiolog
result
copd
patient
monthli
sputa
collect
prospect
case
exacerb
collect
period
year
evalu
identif
type
done
standard
method
phenotyp
variant
identifi
h
haemolyticu
independ
method
rdna
sequenc
mlst
hybrid
dnadna
sequenc
gene
encod
protein
total
strain
studi
sputum
isol
nasopharing
isol
genotyp
characterist
h
haemolyticu
none
invas
isol
studi
genotyp
characterist
h
haemolyticu
molecular
type
sputum
isol
made
possibl
demonstr
statist
signific
differ
acquisit
new
strain
h
influenza
causal
agent
exacerb
patient
copd
vs
p
rr
ic
differ
case
h
haemolyticu
signific
vs
p
rr
ic
result
studi
infer
h
haemolyticu
frequent
inhabit
respiratori
tract
children
adult
copd
commens
without
pathogen
capac
unfortun
standard
methodolog
use
identif
h
influenza
possibl
identif
phenotyp
variant
h
haemolyticu
fact
might
import
clinic
implic
use
antibiot
treatment
mani
patient
persist
nontyp
haemophilu
influenza
nthi
patient
copd
thought
relat
interact
bacterium
human
alveolar
macrophag
immun
mechan
mediat
macrophag
respons
poorli
known
aim
studi
demonstr
import
alter
immun
respons
alveolar
macrophag
persist
nthi
lower
airway
patient
copd
three
group
patient
includ
esmok
copd
n
esmok
without
copd
n
nonsmok
n
respiratori
blood
sampl
use
separ
purifi
macrophag
phagocytosi
adher
cell
surviv
intracellular
nthi
three
differ
strain
nthi
patient
copd
use
alveolar
macrophag
copd
patient
diminish
phagocytosi
compar
macrophag
two
group
front
three
strain
howev
phagocytosi
nthi
blood
macrophag
similar
three
group
studi
final
intracellular
surviv
nthi
alter
alveolar
macrophag
patient
copd
result
studi
demonstr
exist
alter
immun
respons
alveolar
macrophag
patient
copd
vs
nthi
sown
diminut
phagocytosi
explain
persist
organ
airway
absenc
alter
blood
macrophag
indic
exist
compartmentalis
immun
respons
popul
howev
intracellular
lysi
nthi
alter
alveolar
macrophag
copd
patient
control
pertussi
infect
optim
neither
vaccin
natur
infect
induc
longliv
immun
estim
annual
incid
clinic
pertussi
infect
usa
adolesc
adult
case
per
personyear
lack
specif
clinic
criteria
limit
avail
standard
serolog
criteria
make
difficult
diagnosi
pertussi
infect
studi
determin
impact
vaccin
adolesc
adult
part
nation
institut
healthsponsor
multicent
prospect
random
acellular
pertussi
vaccin
ap
efficaci
trial
us
recent
report
usa
studi
perform
adult
yearsold
onehalf
subject
receiv
ap
vaccin
onehalf
receiv
hepat
vaccin
control
subject
patient
observ
year
clinic
ill
telephon
call
everi
day
serolog
studi
obtain
baselin
month
month
vaccin
applic
serolog
evalu
iga
igg
antibodi
pertusi
toxin
pt
filament
hemagglutinin
fha
pertactin
prn
antigen
includ
vaccin
fimbria
fim
includ
vaccin
quantit
elisa
seroconvers
rate
antigen
pt
specif
rang
unvaccin
patient
author
estim
infect
rate
among
unvaccin
adult
close
period
vaccin
patient
infect
rate
efficaci
vaccin
difficult
obtain
vaccin
patient
titer
year
equal
higher
titr
month
immun
patient
cutoff
fim
antibodi
antigen
includ
vaccin
significantli
less
common
among
vaccin
subject
among
control
p
suggest
infect
less
frequent
although
margin
signific
vaccin
patient
vaccin
unvaccin
patient
symptom
probabl
relat
pertussi
infect
common
patient
serolog
evid
infect
incid
b
pertussi
infect
adult
per
year
usual
asymptomat
b
pertussi
booster
may
confer
protect
adolesc
adult
symptomat
pertussi
infect
may
reduc
transmiss
other
diagnosi
pertussi
infect
problemat
lack
specif
clinic
criteria
insensit
cultur
pcr
limit
avail
standard
serolog
test
aim
studi
determin
use
sever
procedur
includ
realtim
pcr
laboratori
diagnosi
pertussi
investig
clonal
relationship
among
clinic
isol
bordetella
pertussi
studi
perform
one
tertiari
hospit
madrid
spain
month
august
octob
nasopharyng
swab
collect
paediatr
adult
patient
symptom
pertussi
contact
case
sampl
process
cultur
reganlow
medium
direct
fluoresc
assay
polyclon
antibodi
wall
antigen
realtim
pcr
lightcycl
primer
region
isol
character
pulsedfield
gel
electrophoresi
among
clinic
sampl
correspond
patient
b
pertussi
detect
sampl
cultur
sampl
dfa
sampl
realtim
pcr
realtim
pcr
diagnos
case
cultur
dfa
respect
relat
cultur
sensit
specif
pcr
respect
author
consid
probabl
partial
immun
patient
may
justifi
better
result
pcr
relat
cultur
seventeen
clinic
isol
avail
pfge
analysi
differ
genotyp
identifi
fourteen
isol
includ
two
genotyp
genotyp
c
genotyp
e
realtim
pcr
appli
diagnosi
pertussi
provid
posit
result
dfa
cultur
basi
result
dfa
longer
use
diagnosi
b
pertussi
infect
year
cycl
observ
relat
b
pertussi
infect
independ
vaccin
programm
clone
domin
one
circul
least
sinc
aim
studi
determin
preval
clinic
isol
e
coli
resist
fluoroquinolon
hospitalizad
patient
well
underli
mechan
resist
mutat
gene
gyra
parc
toler
organ
solvent
marker
overexpress
activ
efflux
system
acrab
e
coli
levofloxacin
mic
mgl
studi
fecal
sampl
analys
e
coli
diminish
fluoroquinolon
suscept
isol
isol
levofloxacin
mic
mgl
strain
mean
mutat
gene
gyra
parc
present
toler
organ
solvent
frequent
isol
levofloxacin
mic
mgl
exhibit
mean
one
mutat
gyra
preval
isol
toler
organ
solvent
vari
period
studi
clonal
dissemin
detect
main
conclus
studi
colon
gut
escherichia
coli
reduc
suscept
quinolon
hospitalizad
patient
common
resist
determin
quinolon
vari
time
resist
nalidix
acid
use
identif
strain
e
coli
mutat
gyra
compar
studi
molecular
epidemiolog
escherichia
coli
human
blood
isol
faecal
isol
chicken
faecal
isol
suscept
n
resist
n
ciprofloxacin
analysi
filogenet
group
virul
genotyp
epidemiolog
relationship
rapd
pfge
carri
among
human
isol
resist
ciprofloxacin
differ
ciprofloxacinresist
strain
sensit
resist
isol
chicken
indistinguish
suscept
human
isol
gene
associ
virul
factor
resist
human
isol
suscept
resist
chicken
isol
resist
human
isol
similar
chicken
isol
rapd
pfge
anoth
studi
increas
degre
evid
hypothesi
ciprofloxacin
resist
isol
appear
de
novo
select
pressur
enrofloxacin
quinolon
use
anim
husbandri
suscept
progenitor
anim
gut
transmit
human
via
food
chain
final
caus
infect
human
ciprofloxacinresist
strain
retrospect
studi
predispos
factor
clinic
present
evolut
episod
esblproduc
escherichia
coli
bacteraemia
seen
januari
march
singl
institut
repres
total
case
e
coli
bacteraemia
seen
period
esblharbour
e
coli
produc
ctxm
type
great
major
clonal
relat
nosocomi
origin
geriatr
center
commun
number
case
increas
mean
age
infect
patient
male
foley
cathet
urinari
tract
obstruct
patient
receiv
antimicrobi
recent
past
aminopenicillin
third
gener
cephalosporin
fluoroquinolon
crude
mortal
patient
treat
combin
inhibitor
carbapenem
mortal
compar
mortal
rate
treat
cephalosporin
fluoroquinolon
p
failur
rate
treat
cephalosporin
independ
mic
valu
howev
number
patient
studi
small
find
interpret
caution
area
preval
esblproduc
e
coli
increasingli
repres
therapeut
guidelin
revis
given
characterist
popul
describ
sugger
particularli
import
sepsi
diagnos
old
male
carrier
urinari
cathet
treat
antimicrobi
recent
past
auhor
decrib
case
year
old
woman
prosthet
mitral
valv
klebsiella
pneumonia
bacteraemia
secondari
infect
intraven
cathet
initi
isol
produc
esbl
suscept
ciprofloxacin
mic
mgl
piperacillintazobactam
pt
patient
combin
ciprofloxacin
amikacin
recurr
bacteraemia
day
later
time
blood
isol
resist
ciprofloxacin
mic
mgl
echocardiogram
show
veget
prosthet
valv
ciprofloxacin
replac
piperacillintazobactam
howev
two
week
treatment
bacteraemia
persist
repeat
blood
cultur
grew
pt
resist
e
coli
final
patient
underw
prosthet
valv
replac
treat
meropenem
three
isol
genotyp
ident
resist
ciprofloxacin
associ
mutat
gyra
activ
pt
inolcula
ufcml
show
low
inocula
first
two
isol
sensit
pt
third
isol
mic
mgl
use
high
inocula
three
isol
mic
mgl
chang
activ
seen
meropenem
relat
bacteri
inoculum
use
three
isol
suscept
cefoxitin
amikacin
mic
mgl
case
exemplifi
two
import
point
first
possibl
therapeut
failur
pt
case
infect
esblproduc
k
pneumonia
second
combin
amikacin
avoid
emerg
resist
companion
antibiot
instanc
ciprofloxacin
mechan
resist
pt
character
mutat
identifi
gen
bla
could
explain
resist
tazobactam
hand
suscept
cefoxitin
rule
possibl
resist
due
loss
porin
studi
analys
presenc
esblproduc
enterobacteriacea
clinic
sampl
faecal
sampl
popul
seen
emerg
depart
sewag
water
faec
farm
anim
faec
patient
gastroenter
sampl
food
faecal
sampl
cultur
mg
cefotaxim
contain
medium
studi
carri
period
estim
comsumpt
antimicrobi
ambulatori
care
measur
preval
esblproduc
enterobacteriacea
clinic
isol
faecal
sampl
sampl
obtain
patient
gastroenter
preval
sampl
farm
anim
rang
food
note
food
sampl
analys
previous
cook
preval
faecal
carrier
significantli
higher
juli
novemb
compar
period
februari
may
lowest
preval
rate
correspond
period
highest
antibiot
consumpt
given
fact
amoxicilinclavulan
frequent
use
antimicrobi
author
specul
possibl
use
could
reason
lower
detect
esblproduc
strain
howev
impact
variabl
differ
alimentari
habit
increas
comsumpt
uncook
food
summer
consid
preval
esblproduc
enterobacteriacea
area
spain
consider
differ
environ
studi
find
suggest
wide
dissemin
strain
commun
could
transmit
human
via
food
chain
metalobetalactamas
mlb
produc
enterobacteriacea
increasingli
recogn
european
countri
particularli
vim
deriv
greec
identifi
escherichia
coli
enterobact
cloaca
klebsiella
pneumonia
last
speci
consid
endem
countri
vourli
et
al
detect
june
march
singl
institut
greec
seven
proteu
mirabili
isol
resist
cefotaxim
ceftazidim
imipenem
suscept
aztreonam
use
doubl
disk
diffus
assay
edta
imipenem
use
ascertain
product
mlb
unlik
etest
pulsedfield
electrophoresi
analysi
reveal
four
relat
clone
repres
isol
indic
persist
strain
hospit
set
case
metallobetalactamas
identifi
correspond
bla
gene
detect
chromosom
encod
integron
platform
wide
dispers
greec
commonli
associ
plasmid
p
mirabili
isol
recov
form
patient
hospit
prolong
period
time
three
differ
ward
indic
persist
time
dispers
singl
institut
first
descript
p
mirabili
produc
also
illustr
potenti
dissemin
multiresist
isol
articl
also
consid
alert
potenti
failur
etest
strip
detect
mlb
certain
enterobacteriacea
metalobetalactamas
mbl
pseudomona
aeruginosa
mainli
describ
asia
europ
remain
scarc
usa
aboufayc
et
al
detect
three
multiresist
p
aeruginosa
isol
posit
metallobetalactamas
test
continu
surveil
studi
mystic
studi
perform
singl
institut
usa
anderson
cancer
center
year
period
isol
recov
unrel
patient
display
differ
pulsedfield
electrophoresi
pattern
well
differ
ribotyp
suggest
independ
emerg
possibl
carbapenem
usag
two
isol
produc
enzym
one
simultan
wherea
enzym
identifi
remain
one
produc
isol
bla
gene
associ
ident
integron
platform
may
suggest
horizont
gene
transfer
process
patient
treat
carbapenem
interestingli
produc
isol
recov
form
patient
previous
treat
carbapenem
jordan
studi
show
well
document
exampl
select
spread
multiresist
isol
distant
geograph
area
case
produc
pseudomona
aeruginosa
interest
point
address
author
phenotyp
detect
mlb
p
aeruginosa
isol
one
doubl
disc
synergi
approxim
test
edta
neg
imipenem
anoth
one
meropenem
addit
two
isol
doubl
disk
diffus
assay
neg
ceftazidim
use
acid
enhanc
detect
mlb
produc
p
aeruginosa
isol
result
also
illustr
laboratori
difficulti
detect
presenc
mlb
p
aeruginosa
pseudomona
aeruginosa
nosocomi
pathogen
resist
antimicrobi
intrins
acquir
rise
resist
evolv
appear
epidem
caus
strain
suscept
polymyxin
risk
factor
associ
fact
well
known
present
studi
design
know
risk
factor
associ
develop
infect
caus
strain
p
aeruginosa
suscept
polymyxin
retrospect
casecontrol
studi
carriedout
tertiari
hospit
athen
greec
includ
patient
episod
p
aeruginosa
bacteraemia
n
januari
august
case
bacteraemia
caus
strain
suscept
polymyxin
n
control
bacteraemia
caus
strain
suscept
least
polymyxin
carbapenem
n
patient
bacteraemia
caus
p
aeruginosa
strain
suscept
polymyxin
antimicrobi
resist
carbapenem
exclud
n
common
sourc
bacteraemia
pneumonia
unknown
urinari
tract
infect
intraabdomin
infect
differ
factor
evalu
includ
use
antimicrobi
consid
patient
receiv
hospit
least
three
day
mortal
rate
case
control
respect
multivari
logist
regress
model
reveal
factor
associ
develop
infect
caus
strain
p
aeruginosa
suscept
polymyxin
previou
use
carbapenem
p
studi
prove
rapid
emerg
resist
carbapenem
among
patient
infect
p
aeruginosa
receiv
antimicrobi
class
exclus
patient
infect
strain
suscept
polymyxin
resist
carbapenem
major
limit
studi
overestim
use
carbapenem
risk
factor
prompt
criteria
select
control
group
exclud
patient
studi
also
author
comment
occurr
infect
strain
suscept
polymyxin
relat
outbreak
made
molecular
analysi
strain
sure
horizont
transmiss
object
manuscript
review
non
resolv
aspect
infect
caus
acinetobact
baumannii
genu
acinetobact
consist
strictli
aerob
gramneg
cocobacillari
rod
differ
studi
result
descript
genom
speci
valid
relat
habitat
acinetobact
colon
skin
human
be
baumannii
recent
studi
shown
baumannii
unsuspect
reservoir
food
fruit
veget
arthropod
bodi
lice
baumannii
caus
infect
traumat
injuri
iraq
kuwait
afghanistan
vietnam
suggest
environment
contamin
wound
although
sourc
remain
unknown
also
baumannii
show
toler
desicc
baumannii
develop
rapidli
antimicrobi
resist
relat
use
antimicrobi
hospit
multipl
mechan
plasmid
integron
transposon
natur
transform
result
frequent
appear
strain
resist
almost
avail
antimicrobi
frequent
infect
caus
baumannii
affect
respiratori
tract
surgic
wound
urinari
tract
bacteraemia
crude
mortal
high
infect
bacteraemia
ventilatorassoci
pneumonia
although
seem
nonattribut
mortal
casecontrol
studi
frequenc
infect
colonis
baumannii
differ
among
hospit
mostli
nosocomi
incid
paediatr
ward
low
outbreak
infect
baumannii
facilit
resist
desicc
antimicrobi
resist
occur
hospit
area
frequent
intens
care
unit
multipl
risk
factor
identifi
includ
ward
high
densiti
colonizedinfect
patient
environment
contamin
carriag
hand
staff
member
adher
strict
infectioncontrol
measur
use
complex
epidemiolog
baumannii
infect
highlight
exist
centr
endemicepidem
situat
multipl
clone
respons
colonisationsinfect
also
coexist
outbreak
sporad
case
infect
transmiss
strain
among
differ
sanitari
centr
sever
countri
respect
treatment
differ
clinic
studi
shown
efficaci
sulbactam
colistin
treatment
case
infect
caus
multidrug
resist
strain
although
contradictori
result
experiment
model
case
colistin
depth
review
select
aspect
acinetobact
baumannii
infect
author
identifi
sever
field
need
knowledg
virul
baumannii
identif
reservoir
strategi
control
multidrug
resist
strain
treatment
infect
caus
strain
acinetobact
baumannii
nosocomi
pathogen
caus
among
infect
hospitalacquir
pneumonia
hap
previous
report
communityacquir
pneumonia
cap
caus
baumannii
object
manuscript
analyz
clinic
prognost
characterist
cap
baumannii
compar
hap
bacterium
method
retrospect
casecontrol
studi
case
cap
control
hap
carriedout
region
hospit
hong
kong
juli
decemb
pneumonia
defin
clinic
radiograph
criteria
center
diseas
control
prevent
baumannii
consid
definit
pathogen
isol
blood
pleural
fluid
probabl
pathogen
isol
sputum
tracheal
aspir
cultur
nineteen
case
cap
control
hap
analyz
compar
hap
cap
smoker
vs
p
patient
chronic
obstruct
pulmonari
diseas
vs
p
also
clinic
point
view
cap
bacteraemia
frequent
vs
p
presenc
acut
respiratori
distress
syndrom
vs
p
dissemin
intravascular
coagul
vs
p
final
mortal
rate
day
higher
cap
hap
vs
p
factor
associ
mortal
cap
bacteraemia
low
platelet
count
acidosi
dissemin
intravascular
coagul
data
consist
previou
studi
one
limit
result
number
polymicrobi
pneumonia
high
cap
hap
respect
rest
specif
aetiolog
case
control
includ
studi
also
would
use
know
percentag
cap
baumannii
repres
total
case
cap
attend
hospit
period
studi
final
one
hypothesi
studi
possibl
sever
case
cap
baumannii
admit
hospit
